title: Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate.
abstract: 177Lutetium (177Lu) is a member of the family of elements known as lanthanides or rare earths. Monoclonal antibody (MAb) CC49, a murine IgG1, which is reactive with the tumor-associated antigen, TAG-72, has been shown previously to react with a wide range of human carcinomas; CC49 reacts to a different epitope on the TAG-72 molecule than MAb B72.3 and has a higher binding affinity. We report here the first use of a 177Lu-labeled immunoconjugate, 177Lu-CC49, in an experimental therapy model for human carcinoma. 177Lu-CC49 was shown to delay the growth of established LS-174T human colon carcinomas in athymic mice at a single dose of 50 microCi. Overt toxicity was observed with the administration of approximately 500 microCi of 177Lu-CC49 in which 5 of 9 mice died of apparent marrow toxicity. A single administration of 200 or 350 microCi of 177Lu-CC49, however, was shown to eliminate established tumors through the 77-day observation period after MAb administration. Dose fractionation experiments revealed that at least 750 microCi of 177Lu-CC49 (250 microCi/week for 3 consecutive weeks) was well tolerated in that 9 of 10 mice survived. Moreover, this dose schedule was able to eliminate the growth of relatively large (300 mm3) human colon tumor xenografts in 90% of the animals treated. Single-dose and dose fractionation studies were also carried out with an isotype-matched control MAb, 177Lu-MOPC-21. In all dose schedules, a large differential was seen between the therapeutic effects of the 177Lu-CC49 versus that of the 177Lu-control MAb. The merits and limitations of the use of 177Lu-labeled immunoconjugates (in particular, 177Lu-CC49) are discussed in terms of potential novel therapeutics for human carcinoma.
authors.affiliation: Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
authors.forename: J
authors.initials: J
authors.lastname: Schlom
authors.forename: K
authors.initials: K
authors.lastname: Siler
authors.forename: D E
authors.initials: DE
authors.lastname: Milenic
authors.forename: D
authors.initials: D
authors.lastname: Eggensperger
authors.forename: D
authors.initials: D
authors.lastname: Colcher
authors.forename: L S
authors.initials: LS
authors.lastname: Miller
authors.forename: D
authors.initials: D
authors.lastname: Houchens
authors.forename: R
authors.initials: R
authors.lastname: Cheng
authors.forename: D
authors.initials: D
authors.lastname: Kaplan
authors.forename: W
authors.initials: W
authors.lastname: Goeckeler
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000473:pathology / Q000532:radiotherapy*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology / Q000627:therapeutic use*; D008187:Lutetium / Q000493:pharmacokinetics / Q000627:therapeutic use*; D051379:Mice; D008819:Mice, Nude; D011868:Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D014018:Tissue Distribution; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D011868:Radioisotopes; D008187:Lutetium